Soliris (Eculizumab) for Myasthenia Gravis

Overview
Soliris is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat generalized myasthenia gravis (gMG) in adults and children 6 and older who are anti-acetylcholine receptor (AChR) antibody positive. Soliris is also referred to by its drug name, eculizumab.

Soliris is a monoclonal antibody, a type of drug designed to target specific proteins in the body. In treating myasthenia gravis, it is believed to work by disrupting communication between nerves and muscles.

How do I take it?
Prescribing information states that for generalized myasthenia gravis, Soliris is administered through intravenous infusion by a health care professional. The recommended dosage differs for adult and pediatric patients. Your doctor will advise you of the appropriate dosing schedule for your condition. Soliris should be administered exactly as prescribed by a healthcare provider.

Side effects
Common side effects of Soliris in adults with generalized myasthenia gravis include musculoskeletal pain.

Rare but serious side effects may include an increased risk of serious and life-threatening meningococcal infections and infusion-related reactions such as anaphylaxis (severe, life-threatening allergic reaction). Soliris should not be initiated in individuals with unresolved serious Neisseria meningitidis infections.

For more details about this treatment, visit:

Prescribing Information: Soliris (Eculizumab) Injection, for Intravenous Use — Alexion Pharmaceuticals